ALN PCS

Drug Profile

ALN PCS

Alternative Names: ALN-PCS; ALN-PCS01; ALN-PCS02

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Antihyperlipidaemics; Small interfering RNA
  • Mechanism of Action PCSK9 protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 05 Nov 2014 Alnylam receives patent allowance for RNA interference technology in USA
  • 08 Feb 2013 Alynylam and The Medicines Company form an agreement for the global development and commercialisation of ALN PCS for hypercholesterolaemia
  • 12 Nov 2012 Alnylam Pharmaceuticals and Tekmira Pharmaceuticals Corporation sign a new licensing agreement regarding RNAi-based therapies, superseding all previous agreements
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top